Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Day One Biopharmaceuticals Inc DAWN

Healthcare Biotechnology
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or... see more

Current News (NDAQ:DAWN)

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

GlobeNewswire 5 days ago

Day One Announces Preliminary 2025 OJEMDA(TM) Net Product Revenue And Provides 2026 Net Product Revenue Guidance

GlobeNewswire January 11, 2026

Day One Completes Acquisition of Mersana Therapeutics

GlobeNewswire January 6, 2026

Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 16, 2025

Day One Announces Three Year Follow-Up Data From OJEMDA(TM) (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

GlobeNewswire November 24, 2025

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 18, 2025

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

GlobeNewswire November 13, 2025

Day One Announces New OJEMDA(TM) (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

GlobeNewswire November 10, 2025

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

GlobeNewswire November 4, 2025
View More News ››

Opinion & Analysis (NDAQ:DAWN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DAWN)

Using technical analysis for this stock.

This stock is signalling strength to the upside for shareholders today,so good luck to all
coolfooldumbguy - January 12, 2026
View more Bullboard ››

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »

Podcasts